← Back to Company DatabaseVisit Website
Kite Pharma
Pioneering CAR-T cell therapy for blood cancers.
AcquiredSanta Monica, CAFounded 2009
About
Kite Pharma, a Gilead Sciences company, is a leader in chimeric antigen receptor T-cell (CAR-T) therapy for cancer. Its FDA-approved products Yescarta and Tecartus treat certain types of lymphoma and leukemia by engineering patients' own immune cells to fight cancer. Kite was acquired by Gilead in 2017 for approximately $11.9 billion.
Total Funding
$665MKey Product
Yescarta (axicabtagene ciloleucel) CAR-T therapyGeography
North AmericaKey Investors
Gilead SciencesFidelityPerceptive Advisors
Focus Areas
Treatment (Therapeutics)
Technology
Cell TherapyImmunotherapy
Cancer Types
Blood Cancers
Last updated: Feb 4, 2026